Literature DB >> 7539267

Gliotoxin inactivates alcohol dehydrogenase by either covalent modification or free radical damage mediated by redox cycling.

P Waring1, A Sjaarda, Q H Lin.   

Abstract

The fungal metabolite gliotoxin shows selective toxicity to cells of the immune system and has been implicated in the aetiology of invasive aspergillosis. The related toxin sporidesmin is the causative agent of facial eczema in sheep. The toxicity of these compounds has been related to their ability to redox cycle intracellularly and thus produce damaging free radicals. These toxins are also potentially capable of forming mixed disulphides with thiol groups on proteins by virtue of their bridged disulphide structure. We show here that gliotoxin can inactivate horse liver alcohol dehydrogenase by either oxidative damage or covalent modification of thiol groups on the enzyme. Either Cys-281 or Cys-282 is selectively modified. Neither of these residues are at the active site. Covalent modification occurs in the absence of reducing agents such as dithiothreitol. In the presence of dithiothreitol no protection is observed and the rate of inactivation is enhanced although as expected no covalent modification occurs. Gliotoxin can therefore inhibit alcohol dehydrogenase by either pathway and this will depend on the availability of reducing agents such as glutathione and/or how readily the reactive oxygen species generated are removed.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7539267     DOI: 10.1016/0006-2952(95)00039-3

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  15 in total

1.  Disruption of a nonribosomal peptide synthetase in Aspergillus fumigatus eliminates gliotoxin production.

Authors:  Robert A Cramer; Michael P Gamcsik; Rhea M Brooking; Laura K Najvar; William R Kirkpatrick; Thomas F Patterson; Carl J Balibar; John R Graybill; John R Perfect; Soman N Abraham; William J Steinbach
Journal:  Eukaryot Cell       Date:  2006-06

Review 2.  Heteroatom-Heteroatom Bond Formation in Natural Product Biosynthesis.

Authors:  Abraham J Waldman; Tai L Ng; Peng Wang; Emily P Balskus
Journal:  Chem Rev       Date:  2017-04-04       Impact factor: 60.622

3.  Selective inactivation of glutaredoxin by sporidesmin and other epidithiopiperazinediones.

Authors:  Usha Srinivasan; Aveenash Bala; Shu-chuan Jao; David W Starke; T William Jordan; John J Mieyal
Journal:  Biochemistry       Date:  2006-07-25       Impact factor: 3.162

4.  Treatment of murine Th1- and Th2-mediated inflammatory bowel disease with NF-kappa B decoy oligonucleotides.

Authors:  Stefan Fichtner-Feigl; Ivan J Fuss; Jan C Preiss; Warren Strober; Atsushi Kitani
Journal:  J Clin Invest       Date:  2005-10-20       Impact factor: 14.808

Review 5.  Pathogenesis of Aspergillus fumigatus in Invasive Aspergillosis.

Authors:  Taylor R T Dagenais; Nancy P Keller
Journal:  Clin Microbiol Rev       Date:  2009-07       Impact factor: 26.132

6.  A backup plan for self-protection: S-methylation of holomycin biosynthetic intermediates in Streptomyces clavuligerus.

Authors:  Bo Li; Ry R Forseth; Albert A Bowers; Frank C Schroeder; Christopher T Walsh
Journal:  Chembiochem       Date:  2012-10-24       Impact factor: 3.164

Review 7.  Redox-directed cancer therapeutics: molecular mechanisms and opportunities.

Authors:  Georg T Wondrak
Journal:  Antioxid Redox Signal       Date:  2009-12       Impact factor: 8.401

8.  A microbial metabolite synergizes with endogenous serotonin to trigger C. elegans reproductive behavior.

Authors:  Yen-Chih Chen; Mohammad R Seyedsayamdost; Niels Ringstad
Journal:  Proc Natl Acad Sci U S A       Date:  2020-11-16       Impact factor: 11.205

9.  Synthesis and Anticancer Activity of Epipolythiodiketopiperazine Alkaloids.

Authors:  Nicolas Boyer; Karen C Morrison; Justin Kim; Paul J Hergenrother; Mohammad Movassaghi
Journal:  Chem Sci       Date:  2013-04-01       Impact factor: 9.825

10.  Gliotoxin is a dual inhibitor of farnesyltransferase and geranylgeranyltransferase I with antitumor activity against breast cancer in vivo.

Authors:  D M Vigushin; N Mirsaidi; G Brooke; C Sun; P Pace; L Inman; C J Moody; R C Coombes
Journal:  Med Oncol       Date:  2004       Impact factor: 3.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.